Further supporting evidence for the role of low-grade inflammation in the causal pathway towards cardiovascular disease is provided by the recent CANTO trial of the specific IL-1b antagonist Canakinumab which was shown to reduce rates of further myocardial infarction (MI), stroke and death in patients with elevated CRP who were treated following infarction MI [13]. This evidence concerns the gene CRP and myocardial infarction.